GENETIC TECHNOLOGIES LIMITED
ASX:GTGPharmaceuticals, Biotechnology & Life SciencesSuspended from quotationToday’s holders own 97.7% of what they think they own, once every option and right converts.
Not rated — the company is suspended from quotation
This company is suspended from ASX quotation. Scoring is paused until it resumes trading. Not rated means no assessment — not low risk.
GENETIC TECHNOLOGIES LIMITED has 1.34B shares outstanding as of May 2025. The share count change over the past 24 months is not stated, as the filed Appendix 2A series ends earlier. The company completed two capital raises in the past 24 months, totalling A$268K, with the latest being a A$268K placement in May 2025. There are 32M options on issue, representing 2.4% of current shares, with none in the money. An expiry date for these options is not on record. As of the September 2025 quarter, the company reported A$272K in cash, sufficient for approximately 272.2 quarters. No proposed securities issues are pending.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 6 Feb 2026 | 3H · cancellation | GTG : ORDINARY FULLY PAID | 1.34B | Appendix 3H |
| 23 May 2025 | 3H · cancellation | GTG : ORDINARY FULLY PAID | 1.34B | Appendix 3H |
| 23 May 2025 | 3H · cancellation | GTG : ORDINARY FULLY PAID | 1.34B | Appendix 3H |
| 21 May 2025 | 2A · quoted issue | GTG : ORDINARY FULLY PAID | 171.9M | Appendix 2A |
| 21 May 2025 | 2A · quoted issue | GTG : ORDINARY FULLY PAID | 1.31B | Appendix 2A |
Capital raises
2 cash raises in the last 24 months · 0 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
No option supply on record carries an exercise price to pay, so no share price switches any of it on. All 32.0M of it converts on something else — a hurdle that may never be met, or terms the filing does not price.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| GTGAF | Warrants | Price-triggered | — | — | 32.0M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.
Director dealings
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.